Latest & greatest articles for ibuprofen

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ibuprofen or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ibuprofen and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ibuprofen

81. Effect of ibuprofen on cardioprotective effect of aspirin.

Effect of ibuprofen on cardioprotective effect of aspirin. Treatment with ibuprofen might limit the cardioprotective effects of aspirin. We aimed to assess whether patients with known cardiovascular disease who take low-dose aspirin and ibuprofen have increased risk of cardiovascular mortality. We studied 7107 patients who were discharged after first admission for cardiovascular disease between April, 1989, and April, 1997, and who were prescribed low-dose aspirin (<325 mg/day) and survived (...) for at least 1 month. Compared with those who used aspirin alone, patients taking aspirin plus ibuprofen had an increased risk of all-cause mortality (adjusted hazard ratio 1.93, 95% CI 1.30-2.87, p=0.0011) and cardiovascular mortality (1.73, 1.05-2.84, p=0.0305). Our finding lends support to the hypothesis that ibuprofen may interact with the cardioprotective effects of aspirin, at least in patients with established cardiovascular disease.

Lancet2003

82. Ibuprofen for Alzheimer's disease.

Ibuprofen for Alzheimer's disease. BACKGROUND: Non-steroidal antiinflammatory drugs such as ibuprofen may have a role in the treatment of conditions characterized by inflammatory processes. Ibuprofen may attenuate the effects of modulators of inflammation that have been implicated in the pathogenesis of Alzheimer's disease. OBJECTIVES: To investigate the efficacy of ibuprofen treatment for people with Alzheimer's disease. SEARCH STRATEGY: The trials were identified from a search (...) of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 10 December 2002 using the (many) terms listed in the main text of the review. The CDCIG Register is updated regularly and contains records from all major health care databases and many ongoing trials databases. In addition computerized databases and Internet sites pertaining to ibuprofen and Alzheimer's disease were systematically examined by two reviewers independently. Data on ongoing trials of ibuprofen for the treatment

Cochrane2003

83. Ibuprofen for the treatment of a patent ductus arteriosus in preterm and/or low birth weight infants.

Ibuprofen for the treatment of a patent ductus arteriosus in preterm and/or low birth weight infants. BACKGROUND: A patent ductus arteriosus (PDA) complicates the clinical course of preterm infants, increasing their risks of developing chronic lung disease (CLD), necrotizing enterocolitis (NEC), and intraventricular hemorrhage (IVH). Indomethacin is used as standard therapy to close a PDA, but is associated with reduced blood flow to the brain, kidneys and gut. Ibuprofen, another cyclo (...) -oxygenase inhibitor, may be as effective with fewer side effects. OBJECTIVES: To determine the effectiveness and safety of ibuprofen compared to placebo or no intervention for closing a PDA in preterm and/or low birth weight infants. To determine the effectiveness and safety of ibuprofen compared to other cyclo-oxygenase inhibitors (including indomethacin, mefenamic acid) for closing a PDA in preterm and/or low birth weight infants. SEARCH STRATEGY: Randomized (or quasi-randomized) controlled trials

Cochrane2003

84. Ibuprofen 400 mg is effective in women, and women are well represented in trials

Ibuprofen 400 mg is effective in women, and women are well represented in trials Ibuprofen 400 mg is effective in women, and women are well represented in trials Ibuprofen 400 mg is effective in women, and women are well represented in trials Barden J, Edwards J E, Moore R A, McQuay H J Authors' objectives To investigate whether women have been under-represented in trials of ibuprofen and whether there is a clinically meaningful difference between men and women in the efficacy of ibuprofen 400 (...) trials (RCTs) that were double-blind were eligible for inclusion. The review included summary data and IPD, where available. Specific interventions included in the review Studies comparing ibuprofen with placebo were eligible for inclusion. The included studies used a 400-mg single dose of ibuprofen. Participants included in the review Adult patients with moderate or severe post-operative pain were eligible for inclusion. The majority of the included studies were of patients having a third molar

DARE.2002

85. Treating fever in children: paracetamol or ibuprofen?

Treating fever in children: paracetamol or ibuprofen? Treating fever in children: paracetamol or ibuprofen? Treating fever in children: paracetamol or ibuprofen? Purssell E Authors' objectives To compare the effectiveness of paracetamol and ibuprofen as antipyretic medications for children. Searching MEDLINE, EMBASE, CINAHL and the Royal College of Nursing database were searched from 1970. The keywords used were ('children' or 'infants' or 'paediatric' or 'pediatric') and ('fever' or 'febrile (...) ' or 'pyrexia' or ' temperature') and ('paracetamol' or 'acetaminophen') and 'ibuprofen'. Textbooks and reference lists were also searched. Study selection Study designs of evaluations included in the review Studies that reported sufficient statistics to allow the calculation of effect size were eligible. The included studies were randomised controlled trials (RCTs), including double-blind RCTs, and controlled trials in which it was unclear whether they were randomised or not. Specific interventions

DARE.2002

86. Glucosamine therapy compared to ibuprofen for joint pain

Glucosamine therapy compared to ibuprofen for joint pain Glucosamine therapy compared to ibuprofen for joint pain Glucosamine therapy compared to ibuprofen for joint pain Ruane R, Griffiths P Authors' objectives To undertake a mini-review of double-blind randomised controlled trials (RCTs) comparing the effectiveness of oral glucosamine to ibuprofen for the relief of joint pain in osteoarthritis. Searching MEDLINE (from 1966 to present), EMBASE (from 1980 to present), a database provided (...) Comparisons of an oral glucosamine preparation with a standard dose of ibuprofen were eligible for inclusion. Trials that studied glucosamine in sulphate or hydrochloride form were included since the available preparations contain either substance. Studies that assessed intramuscular glucosamine were excluded. Trials that compared glucosamine to any other non-steroidal anti-inflammatory drug or placebo were also excluded, as were trials that examined glucosamine in addition to other analgesics. Trials

DARE.2002

87. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants.

Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. 11988250 2002 05 03 2002 05 22 2015 06 16 0140-6736 359 9316 2002 Apr 27 Lancet (London, England) Lancet Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. 1486-8 We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with ibuprofen in premature infants born at less than 28 weeks (...) of gestation. Echocardiography showed severely decreased pulmonary blood flow. Hypoxaemia resolved quickly on inhaled nitric oxide therapy. We suggest that investigators involved in similar trials pay close attention to pulmonary pressure if hypoxaemia occurs after prophylactic administration of ibuprofen. Gournay V V Department of Perinatology, University Hospital, Nantes, France. Savagner C C Thiriez G G Kuster A A Rozé J-C JC eng Case Reports Clinical Trial Journal Article Randomized Controlled Trial

Lancet2002

88. Safety profile of nonprescription ibuprofen in the elderly osteoarthritis patient: a meta-analysis

Safety profile of nonprescription ibuprofen in the elderly osteoarthritis patient: a meta-analysis Safety profile of nonprescription ibuprofen in the elderly osteoarthritis patient: a meta-analysis Safety profile of nonprescription ibuprofen in the elderly osteoarthritis patient: a meta-analysis Ashraf E, Cooper S, Kellstein D, Jayawardena S Authors' objectives To assess the incidence of adverse experiences among elderly people taking multiple doses of non-prescription ibuprofen (...) in the review Studies had to have at least one treatment group assigned multiple doses of a marketed formulation of ibuprofen for the symptomatic treatment of osteoarthritis. The eligible treatment regimens were 1,200 mg or less per day for 10 days or less (i.e. regimens within the U.S. non-prescription limits). In the included studies 400 mg of ibuprofen was taken three times a day for 3, 6 or 10 days. All of the trials were placebo-controlled. Participants included in the review Studies in people

DARE.2001

89. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus.

A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. 10974130 2000 09 07 2000 09 07 2013 11 21 0028-4793 343 10 2000 Sep 07 The New England journal of medicine N. Engl. J. Med. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. 674-81 Indomethacin is the conventional treatment for hemodynamically important patent ductus arteriosus in preterm infants. However, its use is associated with various side effects. In a prospective study (...) , we compared ibuprofen and indomethacin with regard to efficacy and safety for the early treatment of patent ductus arteriosus in preterm infants. We studied 148 infants (gestational age, 24 to 32 weeks) who had the respiratory distress syndrome and an echocardiographically confirmed, hemodynamically important patent ductus arteriosus. The infants were randomly assigned at five neonatal intensive care centers to receive three intravenous doses of either indomethacin (0.2 mg per kilogram of body

NEJM2000

90. Single dose oral ibuprofen and diclofenac for postoperative pain.

Single dose oral ibuprofen and diclofenac for postoperative pain. BACKGROUND: Ibuprofen and diclofenac are two widely used non-steroidal anti-inflammatory (NSAID) analgesics. It is therefore important to know which drug should be recommended for postoperative pain relief. This review seeks to compare the relative efficacy of the two drugs, and also considers the issues of safety and cost. OBJECTIVES: To assess the analgesic efficacy of ibuprofen and diclofenac in single oral doses for moderate (...) pain of moderate to severe intensity, double-blind design, and random allocation to treatment groups which compared either ibuprofen or diclofenac with placebo. DATA COLLECTION AND ANALYSIS: Data were extracted by two independent reviewers, and trials were quality scored. Summed pain relief or pain intensity difference over four to six hours was extracted, and converted into dichotomous information yielding the number of patients with at least 50% pain relief. This was then used to calculate

Cochrane2000

91. The safety profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis

The safety profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis The safety profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis The safety profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis Kellstein D E, Waksman J A, Furey S A, Binstok G, Cooper S A Authors' objectives To compare the incidence of adverse experiences during the multiple-dose use of non-prescription ibuprofen to a placebo. Searching MEDLINE, EMBASE, BIOSIS (...) ). Specific interventions included in the review Multiple doses of a marketed formulation of racemic ibuprofen, within over the counter (OTC) limits - up to 1200mg/day for a maximum of 10 days, for conditions appropriate for a non-prescription analgesic/antipyretic. Six studies used 1200mg/day and 2 used 800mg/day. Participants included in the review Participants were aged 12-97 with a mean age of 47, 43% male and 86% Caucasian, 9% black, 1% Asian and 4% Hispanic. Outcomes assessed in the review

DARE.1999

92. Effects of ibuprofen on the physiology and survival of hypothermic sepsis

Effects of ibuprofen on the physiology and survival of hypothermic sepsis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club1999

93. Analgesic efficacy of ibuprofen alone and in combination with codeine or caffeine in post-surgical pain: a meta-analysis

Analgesic efficacy of ibuprofen alone and in combination with codeine or caffeine in post-surgical pain: a meta-analysis Analgesic efficacy of ibuprofen alone and in combination with codeine or caffeine in post-surgical pain: a meta-analysis Analgesic efficacy of ibuprofen alone and in combination with codeine or caffeine in post-surgical pain: a meta-analysis Li Wan Po A, Zhang W Y Authors' objectives To estimate the analgesic effect of ibuprofen, and to test whether codeine and caffeine (...) were included. The observation period ranged from 3 to 10 hours. Specific interventions included in the review Oral formulations of ibuprofen, ibuprofen plus codeine, ibuprofen plus caffeine, and placebo. Ibuprofen doses ranged from 50 to 900 mg, codeine from 15 to 60 mg, and caffeine from 50 to 200 mg. Participants included in the review Adults with mild to severe pain resulting from dental, episiotomy, postpartum and other post-operative pain. Patients in eligible ibuprofen and caffeine trials

DARE.1998

94. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.

The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. 9070471 1997 03 27 1997 03 27 2013 11 21 0028-4793 336 13 1997 Mar 27 The New England journal of medicine N. Engl. J. Med. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. 912-8 In patients with sepsis the production of arachidonic acid metabolites by cyclooxygenase increases, but the pathophysiologic role (...) of these prostaglandins is unclear. In animal models, inhibition of cyclooxygenase by treatment with ibuprofen before the onset of sepsis reduces physiologic abnormalities and improves survival. In pilot studies of patients with sepsis, treatment with ibuprofen led to improvements in gas exchange and airway mechanics. From October 1989 to March 1995, we conducted a randomized, double-blind, placebo-controlled trial of intravenous ibuprofen (10 mg per kilogram of body weight [maximal dose, 800 mg], given every six

NEJM1997

95. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants.

Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. 8606475 1996 05 17 1996 05 17 2016 11 23 0098-7484 275 7 1996 Feb 21 JAMA JAMA Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. 539-44 To test whether early postnatal (0 to 3 hours) intravenous administration of ibuprofen will prevent patent ductus arteriosus (PDA) in preterm neonates. Prospective sequential controlled trial with three treatment arms (...) . Level 3 perinatal-neonatal intensive care nursery. Thirty-four premature newborn infants born from February to August 1993 with a mean birth weight of 913 g (range, 565 to 1460 g) and gestational age of 26.9 weeks (range, 22.4 to 31.0). Infants were consecutively assigned within 3 hours of age to treatment with either one dose of ibuprofen lysine (10 mg/kg intravenously) followed by 5 mg/kg per dose intravenously at 24 and 48 hours of age (n = 12), one dose of ibuprofen lysine (10 mg/kg

JAMA1996

96. An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial.

An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. 7884951 1995 04 12 1995 04 12 2016 10 17 0098-7484 273 12 1995 Mar 22-29 JAMA JAMA An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. 929-33 To test the hypothesis that ibuprofen increases the risk of hospitalization for gastrointestinal bleeding, renal failure, or anaphylaxis among febrile children. Randomized double-blind acetaminophen-controlled (...) trial. Outpatient pediatric and family medicine practices. A total of 84,192 children. Patients were randomly assigned to receive 12 mg/kg of acetaminophen, 5 mg/kg of ibuprofen, or 10 mg/kg of ibuprofen. Hospitalizations for acute gastrointestinal bleeding, acute renal failure, and anaphylaxis. A total of 277 patients (0.3%) were unavailable for follow-up. Overall, 795 participants (1%) were hospitalized, primarily for infectious diseases; hospitalization rates did not differ according to treatment

JAMA1995

97. Effect of high-dose ibuprofen in patients with cystic fibrosis.

Effect of high-dose ibuprofen in patients with cystic fibrosis. 7503838 1995 03 30 1995 03 30 2013 11 21 0028-4793 332 13 1995 Mar 30 The New England journal of medicine N. Engl. J. Med. Effect of high-dose ibuprofen in patients with cystic fibrosis. 848-54 Since the inflammatory response to chronic infection contributes to lung destruction in patients with cystic fibrosis, we hypothesized that anti-inflammatory therapy might slow the progression of lung disease. In a double-blind trial, 85 (...) patients, 5 to 39 years of age, with mild lung disease (forced expiratory volume in one second [FEV1], > or = 60 percent of the predicted value) were randomly assigned to receive ibuprofen or placebo orally twice daily for four years. Doses were adjusted individually to achieve peak plasma concentrations of 50 to 100 micrograms per milliliter. Changes in pulmonary function, the percentage of ideal body weight, the chest-radiograph score, and the frequency of hospitalization were assessed. Patients

NEJM1995

98. Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol

Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol Bentkover J D, Baker A M, Kaplam H Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Use of nonsteroidal anti-inflammatory drugs (NSAIDs) for symptomatic relief in patients with arthritic conditions. In particular 1) Nabumetone 1 g/day; 2) Ibuprofen 2.4 g/day; 3) Ibuprofen 2.4 g/day plus misoprostol 800 (micro g/day. Type of intervention Treatment. Economic study

NHS Economic Evaluation Database.1994

99. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.

Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. 2052056 1991 07 22 1991 07 22 2015 11 19 0028-4793 325 2 1991 Jul 11 The New England journal of medicine N. Engl. J. Med. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. 87-91 The optimal short-term, symptomatic (...) therapy for osteoarthritis of the knee has not been fully determined. Accordingly, we compared the efficacy of a nonsteroidal antiinflammatory drug, ibuprofen, given in either an antiinflammatory dose (high dose) or an analgesic dose (low dose), with that of acetaminophen, a pure analgesic. In a randomized, double-blind trial, 184 patients with chronic knee pain due to osteoarthritis were given either 2400 or 1200 mg of ibuprofen per day or 4000 mg of acetaminophen per day. They were evaluated after

NEJM1991

100. Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin.

Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin. 6361565 1984 02 22 1984 02 22 2013 11 21 0028-4793 310 5 1984 Feb 02 The New England journal of medicine N. Engl. J. Med. Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin. 279-83 We investigated whether the glomerular synthesis of prostacyclin modulates the renal (...) blood flow and glomerular filtration rate in chronic glomerular disease. The urinary excretion of 6-keto-prostaglandin F1 alpha, a stable breakdown product of prostacyclin, was significantly (P less than 0.01) reduced in 20 women with chronic glomerular disease, as compared with 19 controls, whereas excretion of urinary prostaglandin E2 was unchanged. In 10 patients randomly assigned to one week of treatment with ibuprofen, excretion of urinary 6-keto-prostaglandin F1 alpha and prostaglandin E2

NEJM1984